Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

104
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
104
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

95
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
95
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

82
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
82
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

85
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
85

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary aortic coarctation repair in adolescents and adults.

JTCVS structural and endovascular·2026
Same author

Open, hybrid, and endovascular repair of recoarctation, aneurysm, and pseudoaneurysm after aortic coarctation repair.

JTCVS techniques·2026
Same author

Dual-Phase Increase in Atrial Arrhythmia Prevalence Following Percutaneous Atrial Septal Defect Closure.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Multimodal Imaging to Guide Stent Placement in a Patient After Fontan Palliation With Restrictive Interatrial Communication.

JACC. Case reports·2025
Same author

Biventricular Fontan conversion in criss-cross, superior-inferior ventricles using arterial switch and extra-anatomical left ventricle to aorta prosthesis.

JTCVS techniques·2025
Same author

Pediatric and Congenital Cardiac Services: An Innovative and Empowering Approach to Global Training and Equitable Care.

Journal of the American Heart Association·2025
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Related Experiment Video

Updated: May 9, 2025

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position
11:20

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position

Published on: April 1, 2022

3.0K

Pulmonary vein stenosis: future optimism.

Patcharapong Suntharos1, Marin Satawiriya2, Lourdes R Prieto3

  • 1Cleveland Clinic Children's Hospital, Cleveland, Ohio.

Current Opinion in Cardiology
|April 30, 2025
PubMed
Summary
This summary is machine-generated.

Pulmonary vein stenosis (PVS) treatment advances, including sirolimus and surgical techniques, improve survival. Frequent reinterventions are key for managing this rare disease and maintaining vein patency.

Keywords:
drug-eluting balloondrug-eluting stentpulmonary vein stenosisrestenosissirolimus

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.8K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.1K

Related Experiment Videos

Last Updated: May 9, 2025

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position
11:20

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position

Published on: April 1, 2022

3.0K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.8K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.1K

Area of Science:

  • Cardiology
  • Pulmonary Medicine
  • Pediatric Cardiology

Background:

  • Pulmonary vein stenosis (PVS) is a rare condition with significant morbidity and mortality.
  • Preventing restenosis in PVS remains a critical clinical challenge.

Purpose of the Study:

  • To review recent therapeutic advances in pulmonary vein stenosis.
  • To highlight therapies demonstrating a survival benefit for PVS patients.

Main Methods:

  • Review of current interventional and surgical strategies for pediatric and adult PVS.
  • Analysis of novel suppressive agents and surgical techniques.
  • Examination of the role of frequent reinterventions and collaborative care.

Main Results:

  • Transcatheter and surgical interventions for pediatric PVS have high restenosis rates, but maintaining vein patency with frequent reinterventions improves outcomes.
  • Local and systemic sirolimus delivery shows promise in reducing restenosis and reinterventions, improving survival.
  • Newer surgical approaches and hybrid techniques offer survival benefits.
  • Adult-onset PVS, though rare, typically responds to transcatheter intervention.

Conclusions:

  • An aggressive strategy of frequent reinterventions is essential for managing PVS.
  • Improved understanding of PVS mechanisms fuels novel multi-pronged therapies yielding better survival.
  • Multispecialty teams and collaborative research are vital for advancing PVS care.